Collegium reports Q3 2026 results with record revenues

Item 2.02 Results of Operations and Financial Condition.

On November 5, 2026, Collegium Pharmaceutical, Inc. (the "Company") issued a press release announcing its financial results for the quarterly period ended September 30, 2026.¹ The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed², under Item 2.02 of this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

On November 5, 2026, Collegium Pharmaceutical, Inc. released an earnings presentation.³ The presentation is attached hereto as Exhibit 99.2 and is being furnished, not filed⁴, under Item 7.01 of this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

EXHIBIT TABLE

Exhibit

No. Description

99.1⁵

Press Release, dated November 5 , 2026⁵

99.2⁵

Earnings Presentation, dated November 5 2026⁵

104 Cover Page Interactive Data File⁵ (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Collegium Pharmaceutical, Inc.

By: /s/ Colleen Tupper

Colleen Tupper

Executive Vice President and Chief Financial Officer

Dated: November 5, 2026

Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance¹⁰

– Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year⁶ –

– Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year –

– Generated AZSTARYS ® Quarterly Net Revenue of $26.5 Million in First Full Quarter of Sales Under Collegium Ownership –

– Generated Quarterly Pain Portfolio Net Revenues of $138.0 Million –

– Announced $50 Million Accelerated Share Repurchase in Q3'26 –

– Conference Call Scheduled for Today at 8:00 a.m. ET –

STOUGHTON, Mass., November 5, 2026 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today reported its financial results for the quarter ended September 30, 2026, and provided a business update.

"We continued to see strong demand across our ADHD portfolio, supported by expanded commercial efforts heading into the back-to-school season. JORNAY PM reached record revenues, prescriptions and prescriber adoption, with quarterly net revenue growing 24% year-over-year," said Vikram Karnani, President and Chief Executive Officer. "Additionally, in the first full quarter of Collegium's ownership of AZSTARYS, revenues exceeded $26.5 million supported by nearly 2% prescription growth year-over-year. This represents a meaningful improvement from AZSTARYS' annual prescription decline in 2025, prior to its acquisition by Collegium. These results demonstrate our ability to rapidly integrate differentiated medicines and execute targeted commercial investments to drive growth. Our pain portfolio also continues to provide a strong financial foundation as we expand our ADHD business and pursue additional opportunities to further grow and diversify Collegium."

"We generated a record $216.3 million in quarterly net revenue and $121.6 million in adjusted EBITDA¹¹, with our ADHD franchise now contributing more than 36% of total revenue," said Colleen Tupper, Chief Financial Officer. "We are reaffirming our full-year 2026 financial guidance and remain committed to deploying capital in a disciplined manner, including executing on business development, paying down debt, and opportunistically returning capital to shareholders to create long-term value. Consistent with our strong cash-generation profile and capital allocation strategy, we expect to complete the previously announced $50 million accelerated share repurchase program before the end of the year, underscoring our confidence in the company's long-term growth prospects."

ADHD Business Highlights

• Generated JORNAY PM net revenue of $51.9 million, up 24% year over year in the quarter ended September 30, 2026⁷ (the 2026 Quarter).

• JORNAY PM prescribers reached an all-time high in the 2026 Quarter with nearly 33,000 healthcare providers writing JORNAY PM prescriptions, up 19% year-over-year.

• Grew JORNAY PM prescriptions 16% year-over-year in the 2026 Quarter.

• Generated $26.5 million in AZSTARYS net revenue in the 2026 Quarter, representing the first full quarter of sales under Collegium's ownership.⁷

• AZSTARYS prescriptions grew nearly 2% in the 2026 Quarter compared to the quarter ended September 30, 2025 (the 2025 Quarter).

• In October, expanded Collegium's commitment to supporting the ADHD community with two new corporate initiatives. Launched Start Talking ADHD, an online resource hub with practical, downloadable guides to help people with ADHD and their families prepare for conversations with healthcare providers, schools and their support networks. Additionally, established a new multi-year partnership with Boston Legacy FC, Boston's professional women's soccer club, focused on promoting inclusion and accessibility through youth coach training, an annual Sports for All Summit and sensory inclusion programs designed to support neurodivergent children and their families.

• In October and November, presented seven abstracts highlighting JORNAY PM and AZSTARYS at two scientific congresses: the American Academy of Child and Adolescent Psychiatry (AACAP) 2026 Annual Meeting and the Neuroscience Education Institute (NEI) Fall Congress. The presentations spanned pediatric clinical studies and research examining daily functioning among adults and caregivers, reflecting Collegium's commitment to building a broader understanding of ADHD across ages and real-life settings.

Pain Portfolio Highlights

• Generated pain portfolio net revenues of $138.0 million in the 2026 Quarter, down 18% year-over-year.⁸

• Generated Belbuca® net revenue of $57.7 million in the 2026 Quarter, down 1% year-over-year.

• Generated Xtampza® ER net revenue of $45.8 million in the 2026 Quarter, down 9% year-over-year.

• Generated Nucynta Franchise net revenue of $30.8 million in the 2026 Quarter, down 44% year-over-year. This included $4.2 million from Hikma Pharmaceuticals USA Inc. (Hikma) for the sale of the authorized generic (AG) versions of Nucynta and Nucynta ER.

Corporate Updates

• In Q3 2026, announced a $50 million accelerated share repurchase program (ASR) as part of Collegium's broader capital allocation strategy.^{9 9}The final settlement of the ASR is expected to be completed in the fourth quarter of 2026.⁹

Upcoming Events

The Company w